Ohio State University Comprehensive Cancer Center
Clinical Trials
327
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (286 trials with phase data)• Click on a phase to view related trials
Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
- Conditions
- Recurrent Malignant GliomaRecurrent WHO Grade 3 GliomaRecurrent WHO Grade 4 GliomaWHO Grade 2 GliomaWHO Grade 3 GliomaWHO Grade 4 Glioma
- Interventions
- Biological: Anti-GARP Chimeric Antigen Receptor-T CellsProcedure: Biospecimen CollectionProcedure: Chest RadiographyProcedure: Echocardiography TestProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanProcedure: PheresisProcedure: Surgical Procedure
- First Posted Date
- 2025-05-09
- Last Posted Date
- 2025-07-09
- Target Recruit Count
- 30
- Registration Number
- NCT06964737
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Pre-Operative Guided Meditation to Reduce Pre-Operative Anxiety in Patients Undergoing Cancer-Directed Surgery
- Conditions
- Hematopoietic and Lymphatic System NeoplasmMalignant Solid Neoplasm
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-04-29
- Target Recruit Count
- 200
- Registration Number
- NCT06949943
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Patient Navigation Intervention for the Improvement of Risk Management Among Women at High Risk of Breast Cancer
- Conditions
- Breast Carcinoma
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-07-03
- Target Recruit Count
- 75
- Registration Number
- NCT06950008
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Perceptions of Vaping Products
- Conditions
- Abuse TobaccoExposure
- First Posted Date
- 2025-03-10
- Last Posted Date
- 2025-03-10
- Target Recruit Count
- 100
- Registration Number
- NCT06868368
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell Lung Cancer
- Conditions
- Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8
- First Posted Date
- 2025-02-10
- Last Posted Date
- 2025-07-11
- Target Recruit Count
- 40
- Registration Number
- NCT06816979
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 66
- Next
News
TAE Life Sciences and Ohio State University Partner to Advance Boron Neutron Capture Therapy for Cancer Treatment
TAE Life Sciences and Ohio State University have formed the first U.S.-based academic-industry alliance focused on developing novel boron-based drug compounds for Boron Neutron Capture Therapy (BNCT).
ACCC Fall 2024: Innovations in Clinical Trial Access, Patient Care, and Treatment Authorization
The Ohio State University Cancer Center's automated informatics program has achieved a 21.9% increase in biosimilar utilization while streamlining prior authorization processes, earning an Innovator Award at ACCC 2024.
First-in-Human Trial Launched for Novel DHODH Inhibitor HOSU-53 in Solid Tumors and Lymphomas
A Phase I/II clinical trial is set to begin at Ohio State University, evaluating the novel DHODH inhibitor HOSU-53 in patients with advanced solid tumors and Non-Hodgkin's lymphoma.